Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich Acquires Cerilliant

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sigma-Aldrich announced Thursday after the close of the market that it has purchased all outstanding shares of Cerilliant, a Texas-based analytical reference standards firm, for an undisclosed amount.

The deal strengthens Sigma-Aldrich's analytical chemistry product portfolio and brings to it more than 2,800 products that support the clinical diagnostics, environmental, nutraceutical, pharmaceutical, forensic, and clinical toxicology markets, the St. Louis-based research products and chemicals firm said in a statement.

Sigma-Aldrich said that the acquisition is anticipated to be neutral to mildly accretive to earnings per share for 2011.

"Their experienced team and capabilities, combined with the quality and breadth of our current analytical brands, our broad scientific knowledge and our powerful global footprint will provide analytical customers around the globe with access to a broad and ever-increasing range of specialized, high-quality analytical standards from a convenient and reliable single source," Russel Gant, VP of the analytical research business at Sigma-Aldrich, said.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.